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Juvenile idiopathic arthritis (JIA) is a rheumatic disease presenting in children \<16 years of age [1](#art40466-bib-0001){ref-type="ref"}, [2](#art40466-bib-0002){ref-type="ref"}, [3](#art40466-bib-0003){ref-type="ref"}. For polyarticular‐course JIA (JIA of any category with ≥5 affected joints [1](#art40466-bib-0001){ref-type="ref"}, [4](#art40466-bib-0004){ref-type="ref"}, [5](#art40466-bib-0005){ref-type="ref"}), methotrexate (MTX) is the recommended first‐line disease‐modifying antirheumatic drug (DMARD) therapy [3](#art40466-bib-0003){ref-type="ref"}. If disease activity remains moderate or high after 3 months of MTX treatment, a biologic agent is frequently initiated and a tumor necrosis factor inhibitor (TNFi) is most commonly employed, followed by an anti--interleukin‐6 agent or abatacept [6](#art40466-bib-0006){ref-type="ref"}. However, it is important to have multiple treatment options in this pediatric population, particularly for patients who are intolerant of or do not respond to MTX or TNFi [2](#art40466-bib-0002){ref-type="ref"}, [7](#art40466-bib-0007){ref-type="ref"}, [8](#art40466-bib-0008){ref-type="ref"}, [9](#art40466-bib-0009){ref-type="ref"}, [10](#art40466-bib-0010){ref-type="ref"}, [11](#art40466-bib-0011){ref-type="ref"}, [12](#art40466-bib-0012){ref-type="ref"}, [13](#art40466-bib-0013){ref-type="ref"}, [14](#art40466-bib-0014){ref-type="ref"}, [15](#art40466-bib-0015){ref-type="ref"} or who live in a tuberculosis‐endemic country.

Abatacept, which selectively modulates the CD80/CD86:CD28 costimulatory signal required for full T cell activation, has a distinct mechanism of action upstream of that of other currently available treatments for rheumatic diseases [13](#art40466-bib-0013){ref-type="ref"}, [16](#art40466-bib-0016){ref-type="ref"}, [17](#art40466-bib-0017){ref-type="ref"}, [18](#art40466-bib-0018){ref-type="ref"}. In adults with rheumatoid arthritis (RA), intravenous (IV) abatacept inhibits structural damage, reduces disease progression, and improves function and health‐related quality of life, with good safety and tolerability [16](#art40466-bib-0016){ref-type="ref"}, [19](#art40466-bib-0019){ref-type="ref"}, [20](#art40466-bib-0020){ref-type="ref"}. IV‐administered abatacept has been proven effective and well tolerated in polyarticular JIA clinical trials and real‐world settings [21](#art40466-bib-0021){ref-type="ref"}, with benefits of treatment sustained up to 7 years in patients ages 6--17 years [2](#art40466-bib-0002){ref-type="ref"}, [9](#art40466-bib-0009){ref-type="ref"}, [13](#art40466-bib-0013){ref-type="ref"}. A subcutaneous (SC) abatacept formulation is also available, allowing for administration at home, thus providing greater flexibility [22](#art40466-bib-0022){ref-type="ref"}.

The exposure--response relationship established in RA and JIA has demonstrated that abatacept steady‐state serum trough concentration (C~minss~) is a good predictor of efficacy [23](#art40466-bib-0023){ref-type="ref"}, [24](#art40466-bib-0024){ref-type="ref"}. A C~minss~ of 10 μg/ml has been shown to correlate with near‐maximal efficacy, based on response as assessed by the Disease Activity Score in 28 joints [24](#art40466-bib-0024){ref-type="ref"} in RA and the JIA--American College of Rheumatology 30% improvement criteria (JIA‐ACR 30) [21](#art40466-bib-0021){ref-type="ref"}, [23](#art40466-bib-0023){ref-type="ref"}, [25](#art40466-bib-0025){ref-type="ref"} in JIA. In adults with RA, a weight‐tiered 10 mg/kg monthly IV dose and 125 mg weekly SC fixed dose of abatacept have shown equivalent efficacy and comparable safety [22](#art40466-bib-0022){ref-type="ref"}, but the effectiveness and safety of SC abatacept in polyarticular JIA have yet to be demonstrated in a clinical trial.

The aim of this study was to investigate the pharmacokinetics (PK), effectiveness, safety, and immunogenicity of weekly weight‐tiered treatment with SC abatacept in patients with active polyarticular JIA, including those ≥2 years of age, over a period of 24 months.

Patients and methods {#art40466-sec-0006}
====================

**Study design.** This 24‐month, single‐arm, open‐label, international, multicenter, 2‐part, phase III study [26](#art40466-bib-0026){ref-type="ref"} was initiated in August 2013 and conducted across 48 centers worldwide by members of the Paediatric Rheumatology International Trials Organisation (PRINTO) [27](#art40466-bib-0027){ref-type="ref"} and the Pediatric Rheumatology Collaborative Study Group (PRCSG) (see Appendix [A](#art40466-app-0001){ref-type="app"} for investigators who participated in this study). The study included 2 age cohorts (cohort 1, ages 6--17 years and cohort 2, ages 2--5 years). During the first 4 months (part 1), patients received open‐label SC abatacept weekly, based on body‐weight tier at each study visit (10 to \<25 kg \[50 mg\], 25 to \<50 kg \[87.5 mg\], and ≥50 kg \[125 mg\]) (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract> for rationale for the dosing regimen).

At month 4, JIA‐ACR 30 responders [28](#art40466-bib-0028){ref-type="ref"} were given the opportunity to participate in a 20‐month extension (part 2 of the study) and continue open‐label abatacept treatment according to the previous dosing regimen; part 1 and part 2 formed the 24‐month cumulative period. Also at month 4, JIA‐ACR 30 nonresponders were given the option to continue SC abatacept for an additional 3 months and to discontinue treatment if a JIA‐ACR 30 response was not achieved by month 7. After part 2, long‐term follow‐up began, in which patients who completed both parts of the study entered a post‐study drug access program. The study was conducted in accordance with the Declaration of Helsinki [29](#art40466-bib-0029){ref-type="ref"}, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulations. At each site, an institutional review board or independent ethics committee approved the protocol, consent forms, and any other written information provided to patients or their legal representatives.

**Patients.** Enrolled patients met the International League of Associations for Rheumatology criteria for JIA [4](#art40466-bib-0004){ref-type="ref"} in 1 of the following categories: extended oligoarticular JIA, polyarticular JIA rheumatoid factor (RF) positive, polyarticular JIA RF negative, enthesitis‐related arthritis, psoriatic arthritis, or systemic JIA (with systemic features absent for ≥6 months prior to enrollment). Patients also had a history of ≥5 joints with active disease and active articular disease at baseline, defined as ≥2 active joints and ≥2 joints with limitation of motion.

In addition, patients were naive to treatment with abatacept but may have had an inadequate response or prior intolerance to ≥1 nonbiologic or biologic DMARD, including TNFi. Patients with systemic JIA at onset were restricted to ≤10% of the study population, and those with a prior inadequate response to TNFi or other biologic DMARDs were restricted to ≤30% of the study population (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>). All patients or their legal representatives provided written informed consent prior to study entry.

**Study end points.** The primary end point was abatacept C~minss~ in cohort 1 (ages 6--17 years) at month 4 of the study (end of part 1). Secondary end points included the proportion of patients in cohort 1 achieving JIA‐ACR 30 response by the end of part 1 and the proportion of patients with serious adverse events (SAEs), AEs, AEs leading to discontinuation, death, marked laboratory abnormalities, and positive immunogenic responses (defined as the presence of antibodies reactive with abatacept in serum) [30](#art40466-bib-0030){ref-type="ref"} in both cohorts over parts 1 and 2. Abatacept C~minss~ to month 24 (end of part 2) was an exploratory end point for both cohorts.

Prespecified exploratory efficacy end points for both cohorts included the proportions of patients achieving JIA‐ACR 30, 50, 70, 90, 100 responses or inactive disease (modified criteria), defined as absence of active joints, physician\'s global assessment of disease severity ≤10 mm, and C‐reactive protein (CRP) level ≤0.6 mg/dl (based on the normal range for CRP as defined by the central analysis site) [31](#art40466-bib-0031){ref-type="ref"} over time to the end of part 2. JIA‐ACR response rates were not corrected for MTX or corticosteroid use; however, if patients received an intraarticular corticosteroid injection, the treated joint was designated as active for the following 3 months. Other prespecified exploratory end points for cohort 1 included median post‐baseline values of the 6 JIA‐ACR core set variables: number of active joints, number of joints with limitation of motion, physician\'s global assessment, parent\'s global assessment of patient overall well‐being, cross‐culturally adapted and validated version of the Childhood Health Assessment Questionnaire disability index (C‐HAQ DI) [32](#art40466-bib-0032){ref-type="ref"}, and laboratory marker of acute inflammation (CRP level). Post hoc analyses in both cohorts were conducted to determine the median Juvenile Arthritis Disease Activity Score in 71 joints using the CRP level (JADAS‐71--CRP) [33](#art40466-bib-0033){ref-type="ref"}, [34](#art40466-bib-0034){ref-type="ref"} over time, and the proportion of patients achieving low disease activity according to the JADAS‐71--CRP (cutoff value in polyarthritis ≤3.8) and remission (defined as a JADAS‐71--CRP value of ≤1 for ≥6 months) [33](#art40466-bib-0033){ref-type="ref"}, [35](#art40466-bib-0035){ref-type="ref"}. In addition, post hoc subgroup analyses of JIA‐ACR response rates and proportions of patients achieving JADAS‐71--CRP low disease activity and remission in cohort 1 were performed using baseline concomitant MTX treatment, prior biologic treatment, and JIA category as subgroups (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>).

**Analysis populations.** In both cohorts, the PK analysis population for month 4 (end of part 1) comprised treated patients for whom PK measurements were collected in the 4--10‐day window after the most recent SC dose; these patients also had 7 consecutive weekly SC abatacept injections at the same dosage prior to month 4. The PK analysis population at the time points other than month 4 also comprised those patients with PK measurements collected in the 4--10‐day window after the most recent SC dose.

Effectiveness analyses were conducted on the intent‐to‐treat (ITT) population (defined as all treated patients) for both cohorts in part 1, as prespecified. For part 2, an "as‐observed" analysis was planned for both cohorts. However, in cohort 1 (ages 6--17 years), ITT analyses were also performed for the evaluation of effectiveness (sensitivity analysis), except for median post‐baseline values for JADAS‐71--CRP and the 6 JIA‐ACR core set variables over the cumulative period. In cohort 2 (ages 2--5 years), only as‐observed analyses were performed for part 2, as not all patients had completed treatment at the time of database locking.

Safety analyses were performed on the ITT population in both cohorts, taking into consideration all events during parts 1 and 2. Marked laboratory abnormalities criteria were prespecified (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>). Immunogenicity was assessed in patients in the ITT population for whom ≥1 post‐baseline immunogenicity result was collected.

**Statistical analysis, sample size, and power calculation.** As the aim of this study was to assess the PK of SC abatacept treatment, it was not powered for statistical hypothesis testing. A sample size of \~160 patients for cohort 1 (ages 6--17 years) was planned to allow for assessment of PK, effectiveness, safety, and immunogenicity, resembling the sample size of the 4‐month lead‐in phase of the IV abatacept JIA study [13](#art40466-bib-0013){ref-type="ref"}. Enrollment of \~160 patients into the 3 body‐weight tiers was predicted to ensure that the half‐width of the 90% confidence interval (90% CI) for C~minss~ would be within 18% of the true population mean for each body‐weight tier group, calculated based on a log‐transformed standard deviation for C~minss~ of 0.49. For JIA‐ACR 30 response, a sample of 160 patients would yield a precision of 7.4% for the half‐width of the 95% CI, assuming an underlying true responder rate of 64%, as seen with IV abatacept in JIA [13](#art40466-bib-0013){ref-type="ref"}. For cohort 2 (ages 2--5 years), a sample size of ≥30 patients permitted initial descriptive assessment of PK, effectiveness, safety, and immunogenicity.

All effectiveness, safety, and PK analyses were descriptive, with no formal statistical testing. For effectiveness analyses using the ITT population, patients with missing data were imputed as nonresponders. CIs for proportions were computed using normal approximation, provided that the actual number of events was ≥5; otherwise, computed CIs were calculated using an exact method. In order to investigate the impact of immunogenicity on effectiveness, safety, and PK, a clinical review of the data on effectiveness, safety, and PK for patients who had positive immunogenic responses was performed.

Results {#art40466-sec-0007}
=======

**Patient disposition and baseline characteristics.** A total of 219 patients entered part 1 of the study; 173 were ages 6--17 years (cohort 1) and 46 were ages 2--5 years (cohort 2). As shown in Figure [1](#art40466-fig-0001){ref-type="fig"}, 132 patients (76.3%) in cohort 1 and 24 (52.2%) in cohort 2 completed both parts 1 and 2. In both cohorts, the discontinuation rate was low across both parts of the trial; overall, the main reasons for discontinuation were lack of efficacy, withdrawal of consent, and AEs. Treatment in the cumulative period was ongoing for 15 patients (32.6%) in cohort 2 at the time of database locking. Baseline demographic and disease characteristics for cohorts 1 and 2 are shown in Table [1](#art40466-tbl-0001){ref-type="table"}. Whereas 41.0% of patients (71 of 173) in cohort 1 had a disease duration of ≥2 years, most patients (91.3% \[42 of 46\]) in cohort 2---which included patients as young as 2 years of age---had a disease duration of \<2 years (median 0.5 years). At baseline, 78.6% of patients in cohort 1 and 80.4% in cohort 2 were receiving concomitant MTX. A protocol violation occurred in cohort 1, due to inclusion of 5 patients from noneligible JIA categories in the analysis. The median exposure to abatacept during the cumulative period was 24.3 months (range 1.9--28.0) in cohort 1 and 24.1 months (range 4.0--26.2) in cohort 2.

![Patient disposition. \* = treatment ongoing at time of analysis in 15 patients (32.6%). AEs = adverse events.](ART-70-1144-g001){#art40466-fig-0001}

###### 

Summary of baseline demographics and clinical characteristics of the JIA patients[a](#art40466-note-0005){ref-type="fn"}

  Characteristic                                                                                                    Cohort 1 (n = 173)   Cohort 2 (n = 46)
  ----------------------------------------------------------------------------------------------------------------- -------------------- -------------------
  Age, median (IQR) years                                                                                           13.0 (10.0--15.0)    4.0 (3.0--5.0)
  Female sex                                                                                                        136 (78.6)           28 (60.9)
  Weight, median (IQR) kg                                                                                           45.0 (31.5--57.0)    18.0 (15.0--21.1)
  Weight category                                                                                                                        
  \<25 kg                                                                                                           18 (10.4)            43 (93.5)
  25 to \<50 kg                                                                                                     74 (42.8)            3 (6.5)
  ≥50 kg                                                                                                            81 (46.8)            0
  Ethnicity                                                                                                                              
  White                                                                                                             144 (83.2)           44 (95.7)
  African American                                                                                                  14 (8.1)             1 (2.2)
  Other                                                                                                             15 (8.7)             1 (2.2)
  Disease duration, median (IQR)                                                                                    2.0 (0.0--4.0)       0.5 (0.0--1.0)
  \<2 years                                                                                                         102 (59.0)           42 (91.3)
  2 to \<5 years                                                                                                    37 (21.4)            4 (8.7)
  5 to ≤10 years                                                                                                    30 (17.3)            0
  \>10 years                                                                                                        4 (2.3)              0
  JIA category                                                                                                                           
  Polyarthritis RF negative                                                                                         94 (54.3)            29 (63.0)
  Polyarthritis RF positive                                                                                         46 (26.6)            3 (6.5)
  Extended oligoarthritis                                                                                           19 (11.0)            10 (21.7)
  Systemic arthritis                                                                                                5 (2.9)              0
  Psoriatic arthritis                                                                                               0                    4 (8.7)
  Enthesitis‐related arthritis                                                                                      4 (2.3)              0
  Undifferentiated or persistent oligoarthritis[b](#art40466-note-0006){ref-type="fn"}                              5 (2.9)              0
  JIA‐ACR core set variable, median (IQR)                                                                                                
  No. of active joints                                                                                              10.0 (6.0--19.0)     7.0 (6.0--12.0)
  No. of joints with limitation of motion                                                                           8.0 (4.0--15.0)      8.0 (4.0--11.0)
  Physician global assessment                                                                                       48.0 (31.0--67.0)    50.0 (35.0--60.0)
  Parent\'s global assessment[c](#art40466-note-0007){ref-type="fn"}                                                47.8 (24.1--68.0)    42.1 (17.9--54.7)
  C‐HAQ DI[c](#art40466-note-0007){ref-type="fn"}                                                                   0.9 (0.4--1.5)       1.2 (0.8--1.6)
  CRP, mg/dl[d](#art40466-note-0008){ref-type="fn"}                                                                 0.2 (0.1--0.9)       0.1 (0.1--1.4)
  JADAS‐71--CRP, median (IQR)[e](#art40466-note-0009){ref-type="fn"}                                                21.0 (13.5--30.3)    18.1 (14.0--23.1)
  MTX use at baseline                                                                                               136 (78.6)           37 (80.4)
  MTX dose at baseline, median (IQR) mg/m^2^/week                                                                   11.6 (9.7--14.4)     13.3 (10.9--15.3)
  Route of MTX administration                                                                                                            
  Oral                                                                                                              76 (43.9)            18 (39.1)
  Parenteral[f](#art40466-note-0010){ref-type="fn"}                                                                 60 (34.7)            19 (41.3)
  Oral corticosteroid use at baseline[g](#art40466-note-0011){ref-type="fn"}                                        56 (32.4)            9 (19.6)
  Oral prednisone (or equivalent) dose at baseline, median (IQR) mg/kg/day[h](#art40466-note-0012){ref-type="fn"}   0.1 (0.1--0.2)       0.2 (0.2--0.4)
  Prior biologic use[i](#art40466-note-0013){ref-type="fn"}                                                         46 (26.6)            10 (21.7)

Except where indicated otherwise, values are the number (%) of patients. Cohort 1 consisted of patients ages 6--17 years, and cohort 2 consisted of patients ages 2--5 years. JIA = juvenile idiopathic arthritis; IQR = interquartile range; RF = rheumatoid factor; JIA‐ACR = JIA--American College of Rheumatology criteria for improvement; C‐HAQ DI = Childhood Health Assessment Questionnaire disability index; JADAS‐71‐CRP = Juvenile Arthritis Disease Activity Score in 71 joints using the C‐reactive protein level; MTX = methotrexate.

Protocol violation.

In cohort 1, n = 172.

Normal ≤0.6 mg/dl.

In cohort 1, n = 171.

Includes subcutaneous and intramuscular administration.

Prednisone or prednisolone.

In cohort 1, n = 52; in cohort 2, n = 8.

Adalimumab, etanercept, or tocilizumab.

John Wiley & Sons, Ltd

**Pharmacokinetics.** The median abatacept C~minss~ values at months 4 and 24 in cohort 1 were 40.5 μg/ml (range 9.3--97.0; n = 135) and 43.0 μg/ml (range 0.0--105.2; n = 79), respectively, and were 51.2 (20.1--122.1; n = 30) and 58.7 (26.5--103.7; n = 19) in cohort 2, respectively (Figure [2](#art40466-fig-0002){ref-type="fig"}). Across all weight groups in cohort 1 and overall in cohort 2, the median C~minss~ values were consistent and above the target therapeutic exposure of 10 μg/ml. After the effect of body weight was taken into account, there was no independent age effect on C~minss~ (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>). The results of this study do not indicate that C~minss~ values \>10 μg/ml were associated with either greater effectiveness or an increase in rates of AEs (including infections) at the month 4 time point (data not shown).

![Abatacept steady‐state trough concentration (C~minss~) in patients ages 6--17 years (cohort 1) by weight group (**A**) at month 4 (left) and month 24 (right), and patients ages 2--5 years (cohort 2) at months 4 and 24 (**B**). C~minss~ was summarized for treated patients (≥1 dose of study medication) with evaluable pharmacokinetic measurements at each time point. Data are shown as box plots. Each symbol represents a single subject. Boxes represent the upper and lower interquartile range. Lines inside the boxes represent the median. Whiskers represent the 5th and 95th percentiles. Dashed lines indicate the target therapeutic concentration.](ART-70-1144-g002){#art40466-fig-0002}

**Effectiveness.** In both cohorts, robust JIA‐ACR responses were observed as early as month 1 (Figures [3](#art40466-fig-0003){ref-type="fig"}A and B) (for "as observed" analysis, see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}). At month 4, JIA‐ACR 30 response rates were 83% and 89% in cohorts 1 (n = 173) and 2 (n = 46), respectively. JIA‐ACR 30 response rates in cohorts 1 and 2, respectively, were 75% and 96% at month 21, and 58% and 100% at month 24. Higher‐level JIA‐ACR response rates increased steadily to month 21 (see Figures [3](#art40466-fig-0003){ref-type="fig"}A and B, and [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>). Inactive disease status was achieved at month 4 by 30% and 50% of patients in cohorts 1 and 2, respectively. JIA‐ACR responses were in line with JADAS‐71--CRP scores, per the "as‐observed" analysis, reflecting low disease activity in 42.8% and 90.9% of patients in cohorts 1 and 2, respectively, at month 24. The median JADAS‐71--CRP values were below the cutoff value for low disease activity in polyarthritis by month 7 in cohort 1 and by month 3 in cohort 2; these values reached the lowest level of 1.3 at month 24 in cohort 1, and of 0.5 at month 19 in cohort 2 (Figures [4](#art40466-fig-0004){ref-type="fig"}A and B). In cohort 1, all 6 JIA‐ACR core set variables, including C‐HAQ DI and parent\'s global assessment of patient overall well‐being, improved over time and these values were maintained until the end of the study (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>). Additional results of JIA category analyses (cohort 1) can also be found in the [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}.

![Juvenile Idiopathic Arthritis--American College of Rheumatology (JIA‐ACR) 30, 50, 70, 90 improvement criteria response rates over time for patients ages 6‐17 years (cohort 1; intent‐to‐treat \[ITT\] population analysis) (**A**) and patients ages 2‐5 years (cohort 2; ITT population analysis to month 4 \[study part 1\], "as‐observed" population analysis thereafter to month 24 \[study part 2\]) (**B**). Bars show the 95% confidence intervals. The apparent decrease in response rates at month 24 in cohort 1 reflects a decreased number of patients with available data at this time point and the associated increased proportion of patients imputed as nonresponders due to missing values.](ART-70-1144-g003){#art40466-fig-0003}

![Baseline and post‐baseline Juvenile Arthritis Disease Activity Score in 71 joints using the C‐reactive protein level (JADAS‐71--CRP) in cohort 1 (**A**) and cohort 2 (**B**). Values are the median and interquartile range. JADAS‐71--CRP variables included number of active joints, physician\'s global assessment of disease activity, parent\'s global assessment of patient well‐being, and laboratory measurement of inflammation, as measured by CRP. Dashed lines show the JADAS‐71--CRP cutoff values for inactive disease, low disease activity, and high disease activity (1, 3.8, and 10.5, respectively) [33](#art40466-bib-0033){ref-type="ref"}, [35](#art40466-bib-0035){ref-type="ref"}.](ART-70-1144-g004){#art40466-fig-0004}

**Safety and immunogenicity.** In total, 309.8 and 71.0 patient‐years of follow‐up were available from the safety populations in cohorts 1 and 2, respectively. As shown in Table [2](#art40466-tbl-0002){ref-type="table"}, abatacept was well tolerated in both cohorts throughout the study. AEs occurred in 152 patients (87.9%) in cohort 1 and in 43 patients (93.5%) in cohort 2. SAEs occurred in 14 patients (8.1%) in cohort 1 and 3 (6.5%) in cohort 2. In cohort 1, the incidence rates of AEs and SAEs per 100 patient‐years of exposure were 173.0 (95% CI 147.6--202.8) and 4.7 (95% CI 2.8--7.9), respectively. Two SAEs were considered related to the study drug: sepsis (n = 1; severe intensity) in cohort 1 and overdose (n = 1; mild intensity) in cohort 2, in a patient in whom a higher abatacept dose was administered due to misclassification of weight tier. One malignancy, stage III ovarian germ cell teratoma (severe intensity) was reported in cohort 1 on study day 99, but was considered by the investigator to be unrelated to the study drug. Three autoimmune disorders (none of which were considered related to the study drug) were reported in cohort 1: pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (mild intensity) on study day 71, psoriasis (mild intensity) on study day 327, and Takayasu arteritis (moderate intensity) on study day 416. There were no reported cases of malignancies or autoimmune disorders in cohort 2.

###### 

Adverse events over the 24‐month cumulative period (all treated patients)[a](#art40466-note-0014){ref-type="fn"}

  Event                                                                Cohort 1 (n = 173)                               Cohort 2 (n = 46)
  -------------------------------------------------------------------- ------------------------------------------------ -------------------
  Exposure, patient‐years                                              309.8                                            71.0
  Deaths                                                               0                                                0
  SAEs[b](#art40466-note-0015){ref-type="fn"}                          14 (8.1)                                         3 (6.5)
  Treatment‐related SAEs[c](#art40466-note-0016){ref-type="fn"}        1 (0.6)                                          1 (2.2)
  Discontinuations due to SAEs                                         4 (2.3)[d](#art40466-note-0017){ref-type="fn"}   0
  Incidence rate, per 100 patient‐years                                4.68                                             4.41
  AEs (including SAEs)                                                 152 (87.9)                                       43 (93.5)
  Treatment‐related AEs                                                54 (31.2)                                        27 (58.7)
  Discontinuations due to AEs[e](#art40466-note-0018){ref-type="fn"}   7 (4.0)                                          1 (2.2)
  Incidence rate, per 100 patient‐years                                173.03                                           426.44
  AEs of special interest[f](#art40466-note-0019){ref-type="fn"}                                                        
  Malignancies                                                         1 (0.6)                                          0
  Autoimmune disorders                                                 3 (1.7)                                          0
  Local injection‐site reactions/pain                                  12 (6.9)                                         2 (4.3)
  Infections                                                           118 (68.2)                                       36 (78.3)

Except where indicated otherwise, values are the number (%) of patients.

In cohort 1, serious adverse events (SAEs) included sepsis, abdominal pain, and upper respiratory tract infection (all 3 of which occurred in 1 patient), hypomagnesemia and stage III ovarian germ cell teratoma (both occurred in 1 patient), appendicitis, pneumonia, pyelonephritis, concussion, radius fracture, urinary calculus, nephrolithiasis, anemia, vertigo, chest pain, synovitis, and autonomic nervous system imbalance; in cohort 2, SAEs included overdose, tendon disorder, and febrile convulsion (each in 1 patient).

Treatment‐related SAEs included sepsis of severe intensity in cohort 1 and an overdose of mild intensity (administration of a higher abatacept dose due to misclassification by weight tier) in cohort 2.

Includes discontinuations due to the following SAEs: sepsis, vertigo, stage III ovarian germ cell teratoma, and autonomic nervous system imbalance.

Discontinuations due to sepsis, vertigo, stage III ovarian germ cell teratoma, autonomic nervous system imbalance, exanthema, fatigue, and aphthous ulcer in cohort 1; and pyrexia, rhinitis, and cough (all in 1 patient) in cohort 2.

No opportunistic infections (including extrapulmonary tuberculosis and herpes zoster) related to study drug occurred in either cohort during the study. In cohort 1, stage III ovarian germ cell teratoma was the only malignancy; autoimmune disorders included pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, psoriasis, and Takayasu arteritis.

John Wiley & Sons, Ltd

Local injection site reactions were of mild or moderate intensity and occurred in 12 patients (6.9%) in cohort 1 and 2 (4.3%) in cohort 2 (none of which led to discontinuation). Seven local injection site reactions of moderate intensity occurred in 3 patients in cohort 1, and 1 patient required treatment. The overall rates of patients with infections in cohorts 1 and 2, respectively, were 68.2% and 78.3%. All marked laboratory abnormalities were mild or moderate, and no deaths occurred during the study (for further details, see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>).

Overall, 4 of 172 patients (2.3%) in cohort 1, and 4 of 46 (8.7%) in cohort 2 developed antibodies reactive with abatacept while receiving treatment during the cumulative period, but antibody positivity did not persist. The presence of these antibodies had no apparent effect on PK, effectiveness, or safety (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, available at <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>).

Discussion {#art40466-sec-0008}
==========

In this phase III study of weekly weight‐tiered SC abatacept in patients with polyarticular JIA, the primary end point of abatacept C~minss~ at month 4 in patients ages 6--17 years was shown to be consistently above the planned minimal target therapeutic exposure of C~minss~ 10 μg/ml, without compromising patient safety. The target therapeutic exposure was achieved at month 4 across all weight groups in cohort 1, and overall in cohort 2. SC abatacept was effective and improved function and patient well‐being over the 24‐month cumulative treatment period in both cohorts, with a low rate of discontinuation due to AEs.

The PK data confirm the feasibility of a weekly weight‐tiered SC abatacept treatment regimen for polyarticular JIA in patients ages 2--17 years old (see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}, <http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract>). The observed C~minss~ values were within the ranges of exposure previously found for IV abatacept (10 mg/kg) in patients with JIA [23](#art40466-bib-0023){ref-type="ref"} and in adults with RA receiving IV or SC abatacept treatment [36](#art40466-bib-0036){ref-type="ref"} (also see [Supplementary Materials](#art40466-sup-0001){ref-type="supplementary-material"}). Abatacept C~minss~ values at months 4 and 24 were comparable, demonstrating that the target therapeutic exposure is maintained with continued treatment.

The robust JIA‐ACR response rates and improvements in JADAS‐71--CRP scores to month 24 demonstrated in our study support the use of weekly weight‐tiered SC abatacept therapy in patients with polyarticular JIA. In both cohorts, an early onset of treatment response was observed, with responses maintained throughout the study. In cohort 1, analysis of the 6 JIA‐ACR core variables revealed a beneficial effect of SC abatacept on function (C‐HAQ DI) and well‐being (parent\'s global assessment of patient overall well‐being).

SC abatacept was well tolerated in both cohorts, with no new safety concerns observed. Safety and immunogenicity profiles were similar in cohorts 1 and 2. Although the rate of infections was higher than that observed in a study of adult patients with RA who were treated with abatacept [16](#art40466-bib-0016){ref-type="ref"}, this finding was somewhat expected due to a known greater susceptibility of children to infections as compared with adults. Notably, there were no reported opportunistic infections related to abatacept treatment in patients with polyarticular JIA, even in countries with a high burden of tuberculosis, which is consistent with observations in adults with RA who receive abatacept treatment [37](#art40466-bib-0037){ref-type="ref"}. In addition, there were no malignancies or autoimmune disorders in cohort 2, and the rate of these events was minimal in cohort 1. The safety of SC abatacept was largely consistent with that of IV abatacept in polyarticular JIA [2](#art40466-bib-0002){ref-type="ref"}, [9](#art40466-bib-0009){ref-type="ref"}, [13](#art40466-bib-0013){ref-type="ref"}.

Tolerability of SC injections is of special concern in pediatric patients. In this study, SC abatacept treatment yielded an overall low rate of local injection site reactions, most of which were mild---only a few moderate and no severe reactions were reported. Notably, no local injection site reactions led to treatment discontinuation. Fewer patients developed anti‐abatacept antibodies while receiving SC abatacept treatment compared with IV abatacept treatment [2](#art40466-bib-0002){ref-type="ref"}; this was somewhat expected given that similar trends were observed in a study of adult patients with RA who received SC or IV abatacept plus MTX and had inadequate responses to MTX [22](#art40466-bib-0022){ref-type="ref"}. This finding was also possibly related to the concomitant use of MTX in ≥75% of patients in the current study and differences in study designs.

The effectiveness of SC abatacept treatment demonstrated in the current study constitutes a conservative interpretation of the data. Despite the observational character of the study, an ITT analysis was performed for the cumulative period in cohort 1 and up to month 4 in cohort 2, in which patients discontinuing the study prior to month 24 or not having data available at this time point were imputed as nonresponders.

Abatacept is seldom used to treat polyarticular JIA early in the disease course. The results from cohort 2 in this study, in which abatacept treatment was initiated in patients with a median disease duration of only 0.5 years, provide valuable data regarding the early introduction of abatacept therapy; notably, JIA‐ACR response rates were consistently higher in cohort 2 than in cohort 1.

The study has some limitations, including the open‐label design and a protocol violation, in which a few patients with undifferentiated and persistent oligoarthritis entered the trial despite not meeting the eligibility criteria. Additionally, the use of concomitant medications such as MTX and corticosteroids, as well as prior use of biologic DMARDs (including TNFi) in some patients, may have had confounding effects. However, the sample sizes of the corresponding subgroups were too small to analyze.

In conclusion, weight‐tiered weekly SC abatacept was effective in patients with polyarticular JIA, with no new safety concerns identified. These data suggest that SC abatacept provides an effective and well‐tolerated treatment option for patients with polyarticular JIA, with the additional benefit of the convenience associated with self or parent/caregiver administration of the treatment.
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